KRT5 Antibody

說明書

中文名稱：

KRT5兔多克隆抗體
貨號：

CSB-PA002912
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using CSB-PA002912(KRT5 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA002912(KRT5 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P13647
基因名：

KRT5
別名：

58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human KRT5
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

基因功能參考文獻(xiàn)：
1. Cytokeratin 5/6 and CK8/18 immunohistochemistry on 150 cases of triple negative breast cancers was performed and association with various clinicopathological features was evaluated. PMID: 29884220
2. Data indicate that cytokeratin 5/6 (CK5/6) is an independent prognostic biomarker in urothelial carcinoma and therefore can be used in the prognostic stratification of the patients with bladder cancer. PMID: 29587848
3. CK5/6 expression changed according to the morphological components in adenoid cystic carcinoma of the breast. PMID: 29517206
4. EGFR and CK5/6 expression could serve as biomarkers for identifying triple-negative breast cancer patients with poor survival PMID: 28648939
5. Basal cell carcinoma (BCC) typically shows patchy CD56 expression and diffuse CK5/6 positivity. These 2 markers can be used to distinguish between BCC and Merkel cell carcinoma in challenging cases. PMID: 28403527
6. Negative staining for CK5/6 and p63 can be helpful to distinguish Well-differentiated neuroendocrine tumors (WDNETs) from cutaneous adnexal neoplasms. It is important to consider WDNETs in the differential diagnosis of cutaneous adnexal neoplasms as low-grade tumors may be the first sign of aggressive metastatic disease PMID: 28417484
7. this study adds a further 10 novel mutations to the catalogued genotype-phenotype correlations in epidermolysis bullosa simplex and demonstrates a potential modifying effect of SNPs on the phenotype. We therefore support the notion of full DNA sequencing of both KRT5 and KRT14 genes so as to not miss any variants in the genes contributing to the phenotype. PMID: 28561874
8. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma PMID: 26990746
9. Dual small interfering RNA (siRNA) silencing of RARalpha and RARgamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE PMID: 28692043
10. Cytokeratin 5/6 protein expression as a frequent feature of high-grade serous ovarian carcinoma with various staining patterns. Cytokeratin 5/6 in combination with ER-alpha proved to be a negative prognostic marker. PMID: 28414091
11. The proportion of serous ovarian carcinomas with high K5/6 or high K5 immunostaining was significantly increased following neoadjuvant chemotherapy. K5 can be used to predict serous ovarian cancer prognosis and identify cancer cells that are resistant to chemotherapy. PMID: 28147318
12. CK5 and p40 are good diagnostic markers for squamous cell carcinoma and superior to p63 PMID: 26447895
13. The expression of CK5/6 and of P63 suggests a squamous differentiation including in the basaloid thyroid lymphoepithelial complexes PMID: 27130144
14. Immunocytochemistry using this antibody cocktail comprises five antibodies recognising p63, and cytokeratins ( 7, 18, 5 and 14) showed good sensitivity and specificity for diagnosing breast cancers. Thus, this method is useful for mammary cytology using FNA PMID: 27060708
15. the consistency test results indicated the inter-observer agreement was more robust in MS images for HER2 , CK5/6 and ER than that in RGB images for HER2 , CK5/6 and ER . PMID: 26537585
16. the luminal cells of adenoid cystic carcinoma show a unique aberrant staining pattern for cytokeratin 5/6 that may aid in the differential diagnosis PMID: 27240462
17. Results provide further accumulation of case series of EBS-MP and DPR may provide more accurate diagnostic criteria for genetic disorders of the K5/K14 pair, previously believed to be independent disorders. PMID: 26286811
18. The results introduce a case of special generalized DDD with a family history that clinically resembles dyschromatosis universalis hereditaria (DUH), and suggest that KRT5 may be the candidate gene. PMID: 26440693
19. Authors herein defined two distinct HNSCCs groups (EGFR(+) and K5(+)) with several sub-classes, identifiable by the additional assessment of p53, Bcl2 and CD117. PMID: 26708602
20. identification of 29 different mutations in KRT5 and KRT14, 11 of which were novel, in a Polish cohort of epidermolysis bullosa simplex patients PMID: 26432462
21. KRT5 protein mutation may predispose to a severe lethal variant of epidermolysis bullosa simplex. PMID: 26743602
22. study showed that 34betaE12 is the most appropriate negative marker to combine with alpha-methylacyl coenzyme A racemase as a positive marker for the diagnosis of prostate adenocarcinoma[34betaE12] PMID: 20189848
23. Different staining patterns can be seen with CK5/6 and p63; however, if they are used together with TTF-1 they can be used in subtyping lung neoplasms. PMID: 25944390
24. CK5/6 have roles in biologically aggressive tumors likely to display resistance to trastuzumab ab initio in women diagnosed with HER2+ cancer PMID: 25742793
25. Keratinocytes adhesion and stiffness depends on KRT5 protein missense mutation. PMID: 25961909
26. There were differences between CK5/6, p63,CK34betaE12 and TTF-1 expression with tumor differentiation in squamous cell carcinoma or adenocarcinomas PMID: 25063315
27. in silico analysis of all epidermolysis bullosa simplex causing point mutations on the 2B domain of K5 and K14; result showed all pathogenic point mutations exert their dominant negative effect on the K5/K14 coiled-coil heterodimer complex by altering interchain interaction,leading to changes in stability and assembly competence of the heterodimer complex PMID: 25017986
28. CK5/6, IMP3 and TTF1 immunostaining appears to be useful to improve the accuracy of cytological diagnoses between reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion. PMID: 25337222
29. immunoreactivity cytokeratin 5 and CD44 commonly immunostained Nested/microcystic urothelial carcinoma (US) and some invasive high grade UC PMID: 25143125
30. plectin interacts with keratins 5 and 14 in a process associated with epidermolysis bullosa simplex PMID: 24940650
31. We present six cases from two unrelated Spanish families each with several affected members with epidermolysis bullosa simplex with mottled pigmentation. PMID: 22640275
32. CK5/6, but not c-Met expression, seems to be important in lymphatic metastasis PMID: 24326984
33. In premenopausal patients with hormone receptor-positive breast cancer, tumor protein levels of CK5 correlated positively with BCL6 and are associated with unfavorable clinical outcome. PMID: 23708665
34. The TGFBR3-JUND circuit is conserved in some premalignant lesions that heterogeneously express KRT5. PMID: 24658685
35. The expression of TARP and KRT5 was correlated with the progress of endometrial cancer PMID: 24238509
36. Case Report: novel keratin 5 mutation in an African family with epidermolysis bullosa simplex. PMID: 23450297
37. These results indicate that total expression of mutant KRT5 in the patient's epidermis does not change with aging. PMID: 23588208
38. Repeated progestin treatment and selection of GFP(+) cells enriched for a persistent population of CK5(+) cells. PMID: 23184698
39. Report keratin5 expression in breast papillomas and papillary carcinoma. PMID: 23327593
40. Cytokeratine 5/6 and EGFR expressions showed correlation so these markers are reliable to diagnose basaloid type tumors with a 5% cut-off value. PMID: 23011826
41. Verrucous carcinoma in epidermolysis bullosa simplex is possibly associated with a novel mutation in the keratin 5 gene. PMID: 22639907
42. Two missense mutations identified are in highly conserved regions of KRT14 and KRT5 for epidermolysis bullosa simplex. PMID: 22832485
43. Data show that calretinin and CK5/6 were positive in 100 and 64% of mesotheliomas, and 92 and 31% of reactive effusions, respectively, and desmin was negative in all malignant cases and positive in 85% of reactive effusions. PMID: 23075894
44. All exons of the KRT5 gene and adjacent exon-intron border sequences were amplified using PCR and directly sequenced. RESULTS: We identified a novel keratin 5 (K5) nonsense mutation designated c.C10T (p.Gln4X) in exon 1 of the KRT5 gene PMID: 21569119
45. analysis of Type 1 segmental Galli-Galli disease resulting from a previously unreported keratin 5 mutation [case report] PMID: 22437315
46. the results of CK5/6 and p63 in CNBs of papillary neoplasms were mostly representative of the final results for CK5/6 and p63 in subsequent surgical excisions, excisional biopsy is required for definitive subtyping PMID: 22553810
47. Mutation in K5 gene (c.237C>T)in a family may be responsible for the development of epidermolysis bullosa simplex with mottled pigmentation. PMID: 22161089
48. Defects in K5-K14 filament network architecture cause basal keratinocytes to become fragile, and account for their rupture upon exposure to mechanical trauma. PMID: 22277943
49. we observed a possible association between CK5/6 expression in the primary tumor and multiple versus solitary breast carcinoma brain metastasis PMID: 21427063
50. we suggest that keratin 5/6 and bcl-2 should not be used to identify benign glands in prostate biopsy PMID: 20189848
顯示更多

收起更多
相關(guān)疾病：

Epidermolysis bullosa simplex, Dowling-Meara type (DM-EBS); Epidermolysis bullosa simplex, with migratory circinate erythema (EBSMCE); Epidermolysis bullosa simplex, Weber-Cockayne type (WC-EBS); Epidermolysis bullosa simplex, Koebner type (K-EBS); Epidermolysis bullosa simplex, with mottled pigmentation (MP-EBS); Dowling-Degos disease 1 (DDD1)
蛋白家族：

Intermediate filament family
組織特異性：

Expressed in corneal epithelium (at protein level).
數(shù)據(jù)庫鏈接：

HGNC: 6442

OMIM: 131760

KEGG: hsa:3852

STRING: 9606.ENSP00000252242

UniGene: Hs.433845

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human